Business Model Breakdown
How Veeva Systems Inc Makes Money
VEEV
Market Cap
$24.7B
Annual Revenue
$2.6B
Profit Margin
28.4%
The Short Version
Veeva Systems provides specialized cloud-based software solutions to the global life sciences industry, including pharmaceutical, biotechnology, and medical device companies. Its software helps these companies manage a wide array of mission-critical functions, from drug discovery and clinical trials (R&D Cloud) to commercial operations, sales, and marketing (Commercial Cloud). Veeva primarily generates revenue through recurring subscription fees for access to its highly integrated and industry-specific software applications, which become deeply embedded in customer workflows and are supported by professional services.
Where the Revenue Comes From
Subscription services (~84% of total revenue)
Professional services and other (~16% of total revenue)
Who buys: Global pharmaceutical, biotechnology, and medical device companies, including 15 of the top 20 biopharma companies.
Why It Works (Competitive Advantages)
- ✔Deep industry-specific domain expertise and regulatory compliance focus
- ✔High switching costs due to embedded nature of software in critical workflows
- ✔Integrated cloud platform (Veeva Vault) offering comprehensive solutions
Economic Moat: Wide (Switching Costs, Intangible Assets/IP, Network Effects)
What Our Analysis Says
DVR Score as of April 13, 2026
Veeva Systems remains a top-tier software provider for the life sciences industry, boasting strong competitive moats and a high recurring revenue model. The recent Q4 FY2026 earnings beat, robust FY2027 guidance, and significant share buyback program underscore its exceptional execution and improving profitability. The company's valuation has become more attractive following a recent price drop to a 52-week low ($151.43, down from $~173.2), reducing its market cap to $24.73B from $28.42B just 8 days ago. This lower base, combined with forward P/E and PEG ratios now below industry averages, slightly improves the long-term risk/reward for a 10x growth scenario, making it marginally less improbable. However, achieving such exponential growth from its current large-cap valuation remains highly ambitious, preventing a significantly higher score despite its fundamental strengths. The recent Citigroup downgrade and stock hitting a 52-week low indicate cautious near-term market sentiment, but the underlying business health is strong.